Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biocruces Bizkaia (14)

2023

  1. Nailfold videocapillaroscopy patterns in systemic sclerosis: implications for cutaneous subsets, disease features and prognostic value for survival

    Clinical and experimental rheumatology, Vol. 41, Núm. 8, pp. 1695-1703

  2. Ocular involvement in adult and paediatric patients with monogenic autoinflammatory diseases: a Spanish multicentre retrospective study

    Clinical and experimental rheumatology, Vol. 41, Núm. 10, pp. 2105-2114

2022

  1. Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension (Scientific Reports, (2022), 12, 1, (5289), 10.1038/s41598-022-09353-z)

    Scientific Reports

  2. Gender differences in drug titration among heart failure patients with reduced ejection fraction in the ETIFIC trial

    Revista Espanola de Cardiologia, Vol. 75, Núm. 8, pp. 636-648

  3. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension

    Scientific reports, Vol. 12, Núm. 1, pp. 5289

  4. Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry

    Seminars in Arthritis and Rheumatism, Vol. 55

  5. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)

    Autoimmunity Reviews, Vol. 21, Núm. 10

2021

  1. Corrigendum to ‘Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation’ [AUTREV 19-5 (2020) 102507] (Autoimmunity Reviews (2020) 19(5), (S1568997220300598), (10.1016/j.autrev.2020.102507))

    Autoimmunity Reviews

  2. The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i)

    Rheumatology (Oxford, England), Vol. 60, Núm. 2, pp. 872-880

2020

  1. Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation

    Autoimmunity Reviews, Vol. 19, Núm. 5

2017

  1. New insights into the genetic component of non-infectious uveitis through an Immunochip strategy

    Journal of Medical Genetics, Vol. 54, Núm. 1, pp. 38-46

2016

  1. Off-label use of rituximab for systemic lupus erythematosus in Europe

    Lupus Science and Medicine, Vol. 3, Núm. 1

  2. Patterns of drug therapy in newly diagnosed Spanish patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, Núm. 3, pp. 466-472

2015

  1. Specific association of IL17A genetic variants with panuveitis

    British Journal of Ophthalmology, Vol. 99, Núm. 4, pp. 566-570